[go: up one dir, main page]

唐朝枢 et al., 1993 - Google Patents

Possibility of Targeting Treatment for Ischemic Heart Disease With Liposome (Ⅰ)

唐朝枢 et al., 1993

Document ID
5680884828076998590
Author
唐朝枢
苏静怡
李兆萍
张灵芝
杨军
齐鸣
刘福安
汤健
Publication year
Publication venue
中国科学: 化学英文版

External Links

Continue reading at scholar.google.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
    • A61K47/48192—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes

Similar Documents

Publication Publication Date Title
EP0701448B1 (en) Amplification of the vitamin b 12 uptake system using polymers
AU589587B2 (en) Inert synthetic polymeric carrier combined with bioactive molecule and targetting moieties via peptide spacers
CA2312004A1 (en) Site-specific preparation of polyethylene glycol-grf conjugates
AU4786096A (en) Solid active agent preparations
CA2127463A1 (en) Biodegradable polymers for cell transplantation
CA2219460A1 (en) Lhrh antagonist peptides
EP1327628A3 (en) Lipidization of hydrophilic molecules
CA2333145A1 (en) Drug delivery system comprising a homeobox peptide and a non-peptide, non-nucleotide drug
IL112372A (en) Non-viral vector for the delivery of genetic information to cells
EP0312127A3 (en) Glycosylated insulin derivatives
AU1179795A (en) Improved immunogenic compositions against human gastrin 17
CA2079685A1 (en) Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
CA2147623A1 (en) Novel p-selectin ligand protein
SE9002589D0 (en) NEUTROPHIL ACTIVATING PEPTID-2
EP0228192A3 (en) Renin-inhibitory oligopeptides, their preparation and use
WO1999006388A8 (en) Pharmaceutical compounds isolated from aristolochia taliscana
EP1908772A3 (en) Porphorymonas gingivalis polypeptides and polynucleotides
ATE238348T1 (en) CONJUGATE PEPTIDES DERIVED FROM THYMIC HORMONES, THEIR USE AS MEDICATIONS AND THE COMPOSITIONS CONTAINING THEM
唐朝枢 et al. Possibility of Targeting Treatment for Ischemic Heart Disease With Liposome (Ⅰ)
Miyake et al. Purification and characterization of neutrophil chemotactic factors of Streptococcus sanguis
FI78918C (en) Process for Preparation of Immunomodulator Peptide
AU6273596A (en) Brominated hexahydroxybiphenyl derivatives
KR900014426A (en) SDK peptide, its preparation method and therapeutic composition containing the same
AU2490688A (en) Pharmaceutical product containing vincristine and peptide
任吉民 et al. Effects of lanthanum (Ⅲ) upon cesium (Ⅰ) uptake by human erythrocytes: a (133) _Cs NMR study